| [1] |
Cunningham D, Chua YJ. East meets west in the treatment of gastric cancer[J]. N Eng J Med,2007,357(18):1863-5.
|
| [2] |
Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev,2010,(3): CD004064.
|
| [3] |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative c h e m o t h e r a p y v e r s u s s u r g e r y a l o n e f o r r e s e c t a b l e gastroesophageal cancer[J]. N Eng J Med,2006,355(1):11-20.
|
| [4] |
Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer[J]. Semin Oncol,1998,25 (2 Suppl 5):32-9.
|
| [5] |
De Vita F, Orditura M, Matano E, et al. A phase Ⅱ study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients[J]. Br J Cancer,2005,92(9):1644-9.
|
| [6] |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version1.1)[J]. Eur J Cancer,2009,45(2):228-47.
|
| [7] |
Kuwatani M, Kawakami H, Eto K, et al. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers[J]. Intern Med,2009,48(11):867-75.
|
| [8] |
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma--2nd English edition--response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria[J]. Gastric Cancer,2011,4(1):1-8.
|
| [9] |
Ji JF, Yu Z, Zhong XN, et al. Oxaliplatin-based regimen as neoadjuvant chemotherapy for Chinese patients with advanced gastric cancer: preliminary results of a phase Ⅱ study[J]. J Clin Oncol,2004,22 (14S):4184.
|
| [10] |
Zhang J, Chen RX, Zhang J, et al. Efficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancer[J]. Chin Med J (Engl), 20 12,125(12):2144-50.
|
| [11] |
Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer[J]. J Clin Oncol,2004,22 (4) :658-63.
|
| [12] |
Luo HY, Xu RH, Zhang L, et al. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer[J]. Chemotherapy, 20 08,54(3):228-35.
|
| [13] |
Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-Fu) with epirubicin, cisplatin, and PVI 5-Fu in advanced esophagogastric cancer[J]. J Clin Onco l,2002,20(8):1996-2004.
|
| [14] |
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol,2011,29(13):1715-21.
|
| [15] |
Wang XL, Wu GX, Zhang MD, et al. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer[J]. Oncol Rep,2000,7(2):241-4.
|
| [16] |
Nio Y,Koike M,Omori H,et al.A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer--a single institute study[J]. Anticancer Res,2004,24 (3b) :1879-87.
|
下载:
